Cystatin C in a high-risk combination

Circulation Journal

Volumn 73, Issue 9, 2009, Pages 1593-1594

  Iwanaga, Yoshitaka ^a   Miyazaki, Shunichi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CREATININE; CYSTATIN C; CYSTEINE PROTEINASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ALBUMINURIA; BODY MASS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE SEVERITY; EDITORIAL; EVENT FREE SURVIVAL; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HIGH RISK BEHAVIOR; HOSPITALIZATION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; LABORATORY TEST; LONG TERM CARE; MICROALBUMINURIA; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; PROGNOSIS; PROTEIN DEGRADATION; REVASCULARIZATION; RISK ASSESSMENT; RISK FACTOR; ST SEGMENT ELEVATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CREATININE; CYSTATIN C; GLOMERULAR FILTRATION RATE; HOSPITAL MORTALITY; HUMANS; KIDNEY FAILURE; MYOCARDIAL INFARCTION; PATIENT READMISSION; PREDICTIVE VALUE OF TESTS; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; TIME FACTORS; TREATMENT OUTCOME;

EID: 69549102891     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0351     Document Type: Editorial

References (15)

1. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050-1065.
2. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. Am J Kidney Dis 2002; 40: 221-226. (Pubitemid 34827638)
3. Velagaleti RS, Pencina MJ, Murabito JM, Wang TJ, Parikh NI, D'Agostino RB, et al. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation 2008; 118: 2057-2062.
4. Lewis EF, Moye LA, Rouleau JL, Sacks FM, Arnold JM, Warnica JW, et al; CARE Study. Predictors of late development of heart failure in stable survivors of myocardial infarction: The CARE study. J Am Coll Cardiol 2003; 42: 1446-1453.
5. Takeno M, Yasuda S, Otsuka Y, Morii I, Kawamura A, Yano K, et al. Impact of metabolic syndrome on the long-term survival of patients with acute myocardial infarction: Potential association with C-reactive protein. Circ J 2008; 72: 415-419. (Pubitemid 351600635)
6. Ichimoto E, Jo K, Kobayashi Y, Inoue T, Nakamura Y, Kuroda N, et al. Prognostic significance of cystatin C in patients with ST-elevation myocardial infarction. Circ J 2009; 73: 1669-1673.
7. Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L. Cystatin C: A novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 2004; 110: 2342-2348. (Pubitemid 39407337)
8. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: Data from the Heart and Soul Study. Circulation 2007; 115: 173-179.
9. Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: More than simply a marker of glomerular filtration rate. Clin Chem 2005; 51: 321-327. (Pubitemid 40175801)
10. Hillege HL, van Gilst WH, van Veldhuisen DJ, Navis G, Grobbee DE, de Graeff PA, et al; CATS Randomized Trial. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: The CATS randomized trial. Eur Heart J 2003; 24: 412-420.
11. Windhausen F, Hirsch A, Fischer J, van der Zee PM, Sanders GT, van Straalen JP, et al; for the Invasive versus Conservative Treatment in Unstable Coronary Syndromes (ICTUS) Investigators. Cystatin C for enhancement of risk stratification in non-ST elevation acute coronary syndrome patients with an increased Troponin T. Clin Chem 2009; 55: 1118-1125.
12. Berton G, Cordiano R, Mazzuco S, Katz E, De Toni R, Palatini P. Albumin excretion in acute myocardial infarction: A guide for long-term prognosis. Am Heart J 2008; 156: 760-768.
13. Noto D, Cefalu' AB, Barbagallo CM, Pace A, Rizzo M, Marino G, et al. Cystatin C levels are decreased in acute myocardial infarction: Effect of cystatin C G73A gene polymorphism on plasma levels. Int J Cardiol 2005; 101: 213-217. (Pubitemid 40637615)
14. Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004; 65: 1416-1421. (Pubitemid 38406982)
15. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002; 137: 555-562.